Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Lifesci Capital upped their FY2025 earnings estimates for shares of Enliven Therapeutics in a research report issued to clients and investors on Monday, March 17th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($2.54) per share for the year, up from their prior forecast of ($2.57). The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share.
A number of other research firms also recently commented on ELVN. BTIG Research assumed coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price objective for the company. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research report on Friday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of "Buy" and an average target price of $38.75.
Read Our Latest Report on Enliven Therapeutics
Enliven Therapeutics Stock Up 0.8 %
Shares of ELVN traded up $0.16 during mid-day trading on Wednesday, hitting $21.08. The stock had a trading volume of 407,065 shares, compared to its average volume of 269,341. Enliven Therapeutics has a fifty-two week low of $15.96 and a fifty-two week high of $30.03. The company has a market cap of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04. The company's fifty day simple moving average is $21.31 and its two-hundred day simple moving average is $23.77.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter.
Insider Activity
In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total value of $257,625.00. Following the completion of the transaction, the insider now directly owns 1,002,688 shares in the company, valued at $20,665,399.68. This trade represents a 1.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Benjamin Hohl sold 1,000 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at $325,520. This represents a 7.14 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,784 shares of company stock worth $1,610,375. Insiders own 29.20% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Polar Capital Holdings Plc boosted its position in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after buying an additional 1,739,668 shares during the period. Boxer Capital Management LLC acquired a new stake in Enliven Therapeutics during the 4th quarter worth about $15,106,000. FMR LLC boosted its position in Enliven Therapeutics by 10.6% during the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company's stock worth $160,804,000 after acquiring an additional 601,611 shares during the period. Lord Abbett & CO. LLC purchased a new position in Enliven Therapeutics during the 3rd quarter valued at about $8,199,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock valued at $26,611,000 after purchasing an additional 313,019 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
